Edition:
United States

GlaxoSmithKline PLC (GSK)

GSK on New York Consolidated

40.96USD
19 Jul 2019
Change (% chg)

$-0.45 (-1.09%)
Prev Close
$41.41
Open
$41.09
Day's High
$41.14
Day's Low
$40.94
Volume
1,733,205
Avg. Vol
2,360,081
52-wk High
$42.32
52-wk Low
$36.41

About

GlaxoSmithKline plc is a global healthcare company. The Company operates through three segments: Pharmaceuticals, Vaccines and Consumer Healthcare. The Company focuses on its research across six areas: Respiratory diseases, human immunodeficiency virus (HIV)/infectious diseases, Vaccines, Immuno-inflammation, Oncology and Rare... (more)

Overall

Beta: 0.71
Market Cap(Mil.): $102,300.40
Shares Outstanding(Mil.): 2,494.08
Dividend: 0.47
Yield (%): 4.96

Financials

  GSK Industry Sector
P/E (TTM): 20.39 30.29 34.03
EPS (TTM): 2.03 -- --
ROI: 13.71 13.03 12.70
ROE: 204.26 14.20 17.29

Swiss agree to extradite Chinese scientist to U.S. on theft charges

ZURICH Switzerland has agreed to extradite a Chinese researcher to the United States where prosecutors have charged him with helping his scientist sister steal secrets allegedly worth $550 million from British drugmaker GlaxoSmithKline.

Jul 17 2019

Swiss agree to extradite Chinese scientist to U.S. on theft charges

ZURICH, July 17 Switzerland has agreed to extradite a Chinese researcher to the United States where prosecutors have charged him with helping his scientist sister steal secrets allegedly worth $550 million from British drugmaker GlaxoSmithKline.

Jul 17 2019

As steep patent cliff looms, Shionogi moves to develop its own U.S. sales staff

TOKYO For much of its 141-year history, Japan's Shionogi & Co Ltd has played safe when selling its drugs in the United States and other overseas markets - relying on bigger partners to promote its products and avoiding the cost of maintaining a large sales force.

Jul 16 2019

GSK's two-drug HIV Dovato treatment meets main goal in study

(This July 10 story corrects to show patients switched from Gilead's Descovy, not Gilead's Vemlidy, in fifth paragraph)

Jul 16 2019

CORRECTED-UPDATE 2-GSK's two-drug HIV Dovato treatment meets main goal in study (July 10)

July 10 GlaxoSmithKline Plc's two-drug HIV regimen Dovato was successful in suppressing the AIDS-causing virus in patients over 48 weeks at the same level of a previous three-drug treatment in a late-stage trial, the drugmaker said on Wednesday.

Jul 16 2019

CORRECTED-UPDATE 1-GSK's Dovato suppresses AIDS virus at same levels of 3-drug regimen (July 10)

July 10 GlaxoSmithKline Plc's two-drug HIV regimen Dovato was successful in suppressing the AIDS-causing virus in patients over 48 weeks at the same level of a previous three-drug treatment in a late-stage study, the drugmaker said on Wednesday.

Jul 16 2019

GSK drug helps ovarian cancer patients live longer in late-stage study

GlaxoSmithKline Plc's cancer treatment Zejula met the main goal of helping patients with ovarian cancer live longer without their disease worsening in a late-stage study, the company said on Monday.

Jul 15 2019

UPDATE 2-GSK drug helps ovarian cancer patients live longer in late-stage study

* Study meets main goal of improvement in progression free survival

Jul 15 2019

GSK's ovarian cancer treatment meets main goal in late-stage study

July 15 GlaxoSmithKline said on Monday a late-stage study testing Zejula as a maintenance therapy in patients with first-line ovarian cancer showed positive headline results.

Jul 15 2019

GSK in talks to name HSBC's Symonds as its next chairman: Bloomberg

GlaxoSmithKline Plc is in talks to name HSBC's deputy chairman Jonathan Symonds as the next chairman of the British drugmaker, Bloomberg reported on Sunday, citing a person familiar with the matter.

Jul 14 2019

Earnings vs. Estimates